

**THERATECHNOLOGIES TO ANNOUNCE FINANCIAL RESULTS  
FOR FOURTH QUARTER AND FISCAL YEAR 2020**

News Release

**Montreal, Canada – February 11, 2021 - Theratechnologies Inc.** (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced, today that it will issue its financial results for the fourth quarter and fiscal year ended November 30, 2020 on Thursday, February 25, 2021.

A conference call will be held on February 25, 2021 at 8:30 a.m. (ET) to discuss the results. The call will be hosted by Paul Lévesque, President and Chief Executive Officer. The conference call will be open to questions from financial analysts. Media and other interested individuals are invited to participate in the call on a “listen-only” basis.

The conference call can be accessed by dialing 1-844-400-1697 (toll free) or 1-703-736-7400 (International). The conference call will also be accessible via webcast at <https://edge.media-server.com/mmc/p/2ndpjwpm>. Audio replay of the conference call will be available on the same day starting at 12:00 p.m. (ET) until March 04, 2021, by dialing 1-855-859-2056 (North America) or 1-404-537-3406 (International) and by entering the access code: 8274898. The audio replay is also available until February 25, 2022 on <https://edge.media-server.com/mmc/p/2ndpjwpm>.

**About Theratechnologies**

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at [www.theratech.com](http://www.theratech.com), on SEDAR at [www.sedar.com](http://www.sedar.com) and on EDGAR at [www.sec.gov](http://www.sec.gov).

-30-

**For media inquiries:**

Denis Boucher  
Vice President, Communications and Corporate Affairs  
514-336-7800

**For investor inquiries:**

Leah Gibson  
Senior Director, Investor Relations  
617-356-1009  
[lgibson@theratech.com](mailto:lgibson@theratech.com)